Multiple Sclerosis Therapeutics Market, by Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI5418 | Publish Date: March 2024 | No. of Pages: 178

Global Multiple Sclerosis Therapeutics Market Overview

Introduction:

Multiple Sclerosis (MS) is condition affects brain and spinal cord, in which nerve coating (myelin) gets damaged and causes a range of symptoms, including problems with vision, arm or leg movement, sensation or balance. Once diagnose, MS stays as a lifelong condition, causing serious disability. MS is most commonly diagnosed in people at 20 to 30 ages, although it can develop at any age. In addition, it is more common among women than men. In MS, resulting nerve damage disrupts communication between the brain and the body. Multiple sclerosis causes many different symptoms, including vision loss, pain, fatigue and impaired coordination. The symptoms, severity and duration can vary from person to person. Some people may be symptom free for most of their lives, while others can have severe, chronic symptoms that never go away. Physiotherapy and medication that suppress the immune system can help with symptoms, and slow disease progression. The Multiple Sclerosis Therapeutics Market accounted for US$ 25.86 billion in 2020 and is estimated to be US$ 46.71 billion by 2030 and is anticipated to register a CAGR of 6.1%.

Global Multiple Sclerosis Therapeutics Market Dynamics

Increase prevalence of multiple sclerosis

Currently, there is no cure for MS however; number of treatment can help to control the condition. Treatment modalities are depends on specific symptoms and difficulties of patient, which includes treating relapses with short courses of steroid medication, disease modifying therapies, and specific treatments for individual MS symptoms. Increasing prevalence of multiple sclerosis among the global population, along with extensive research and development (R&D) activities undertaken by key players and government research organizations will accelerate the market growth

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Multiple Sclerosis Therapeutics Market Segmentation

The multiple sclerosis therapeutics market has been segmented on the basis of drug class, route of administration, distribution channel, and region.

On the basis of drug class, the multiple sclerosis therapeutics market is segmented into beta interferon, corticosteroids, monoclonal antibodies, antineoplastic agents, and others. Route of administration in multiple sclerosis therapeutics market segmented into oral and injectable.  Further, the distribution channel for multiple sclerosis therapeutics market includes hospital pharmacies, retail pharmacies, and online pharmacies.

Regional Insights:

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

North America is expected to dominate the multiple sclerosis therapeutics market. Factors responsible for growth of the market includes substantial rise in the awareness among the people regarding various risk factors to cause multiple sclerosis. In addition, high diagnostic rate in the U.S. which leads to significant rise in prescription rates in this region to gain the dominance in the market. Asia Pacific region offers lucrative growth opportunities in multiple sclerosis market, owing to increasing engagement of key players by collaboration with local key players in attempt to capture the market by offering novel treatment therapy, in the region.    

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Drug Class: Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, and Others

By Route of Administration: Oral and Injectables

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Detailed Segmentation:

Multiple Sclerosis Therapeutics Market, By Region:

  • North America
    • Middle East & Africa
      • Middle East & Africa  Multiple Sclerosis Therapeutics Market, By Drug Class
      • Middle East & Africa  Multiple Sclerosis Therapeutics Market, By Route of Administration
      • Middle East & Africa  Multiple Sclerosis Therapeutics Market, By Distribution Channel Industry
      • Middle East & Africa  Multiple Sclerosis Therapeutics Market, By Country
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
      • Latin America  Multiple Sclerosis Therapeutics Market, By Drug Class
      • Latin America  Multiple Sclerosis Therapeutics Market, By Route of Administration
      • Latin America  Multiple Sclerosis Therapeutics Market, By Distribution Channel
      • Latin America  Multiple Sclerosis Therapeutics Market, By Country
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
      • Asia Pacific  Multiple Sclerosis Therapeutics Market, By Drug Class
      • Asia Pacific  Multiple Sclerosis Therapeutics Market, By Route of Administration
      • Asia Pacific  Multiple Sclerosis Therapeutics Market, By Distribution Channel
      • Asia Pacific  Multiple Sclerosis Therapeutics Market, By Country
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
      • Europe  Multiple Sclerosis Therapeutics Market, By Drug Class
      • Europe  Multiple Sclerosis Therapeutics Market, By Route of Administration
      • Europe  Multiple Sclerosis Therapeutics Market, By Distribution Channel
      • Europe  Multiple Sclerosis Therapeutics Market, By Country
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • North America  Multiple Sclerosis Therapeutics Market, By Drug Class
    • North America  Multiple Sclerosis Therapeutics Market, By Route of Administration
    • North America  Multiple Sclerosis Therapeutics Market, By Distribution Channel
    • North America  Multiple Sclerosis Therapeutics Market, By Country
      • The U.S.
      • Canada

Global Multiple Sclerosis Therapeutics Market Key Players

Key players operating in the multiple sclerosis therapeutics market includes Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck KGaA, Biogen Inc., Sanofi S.A., F. Hoffmann-La Roche AG, AbbVie, Inc., and Pfizer, Inc.

Global Multiple Sclerosis Therapeutics Market Company Profile

  • Bayer AG
    • Pfizer, Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • AbbVie, Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • F. Hoffmann-La Roche AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Sanofi S.A.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Biogen Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Merck KGaA
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Novartis AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Teva Pharmaceutical Industries Ltd.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance

Global Multiple Sclerosis Therapeutics Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for Multiple Sclerosis Therapeutics Market Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation , By Drug Type,  2020 – 2030, (US$ Bn)
    • Overview                          
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Beta Interferon
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Corticosteroids
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Monoclonal Antibodies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Antineoplastic Agents
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  6. Market Segmentation , By Route of Administration,  2020 – 2030, (US$ Bn)
    • Overview                
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Injectables
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  7. Market Segmentation , By Distribution Channel, 2020 – 2030, (US$ Bn)
    • Overview                   
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  8. Global Market , By Region, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  10. Company Profiles
    • Bayer AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Teva Pharmaceutical Industries Ltd.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Novartis AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Merck KGaA
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Biogen Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Sanofi S.A.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • F. Hoffmann-La Roche AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • AbbVie, Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
    • Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

The Last Word

  • Future Impact
  • About Us
  • Contact

FAQs

The Multiple Sclerosis Therapeutics Market has been segmented on the basis of form, material type, end-user industry and region.

Multiple Sclerosis Therapeutics are expected to be cheaper in use in due time than their currently used traditional counterparts because of their increased reliability, low maintenance (fewer inspections and repairs), and longer lifetime.

Europe region dominates the Multiple Sclerosis Therapeutics Market.

Key players in the Multiple Sclerosis Therapeutics Market includes, Acciona S.A., Akzo Nobel N.V., Applied Thin Films, Inc. (ATFI), Autonomic Materials Inc., BASF SE, Covestro AG, Critical Materials S.A., Devan Chemicals N.V., E. I. Du Pont De Nemours and Company, and Sensor Coating Systems Ltd.